Device Trial Radar · NCT07325461
Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Feb 18, 2026
Primary completion
Jun 24, 2026
Study completion Jun 24, 2026
Sponsor
- Lead sponsor
- Tandem Diabetes Care, Inc.Public (TNDM)
- Sponsor type
- Industry
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This feasibility study is a prospective, single center, multi-arm study evaluating possible enhancements to the SteadiSet extended wear infusion set.
Conditions
- Diabetes Mellitus, Type 1
Interventions
SteadiSet Infusion SetDevice
Participants will use the SteadiSet Infusion set with an enhanced filling process for three wear periods and the Steadiset Infusion Set only for three wear periods.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 7 Day Survival of Infusion Set for Primary Outcome MeasureTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University
Stanford, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.